Book a free consultation
A no-obligation conversation with our care team, arranged through KPCIRC.
Book a consultationSignature · profiling from a tumour block
Signature STt O
Comprehensive genomic profiling performed directly on tumour tissue, for a rich and direct read of the cancer’s biology.
01Tissue, FFPE
Comprehensive profiling from a tumour block
When tissue is available it can offer high tumour content and a rich, direct read of the cancer’s biology. STt O profiles a formalin-fixed, paraffin-embedded block or slides comprehensively.
02
When tissue is preferred
- A recent, representative block already exists from surgery or biopsy.
- The tumour sheds little DNA into blood, making liquid biopsy less informative.
- Your team wants a tissue-based profile as the primary source.
Image placeholder
An FFPE block and slides in the laboratory
03
What it includes
Comprehensive coverage
SNVs, InDels, fusions and copy number.
Full immune profile
TMB, MSI and MMR, plus mutational signatures.
Pharmacogenomics
The 35-gene drug-response panel.
All six layers
Feeding the complete Blueprint Care report.
04
Tissue or blood?
| Tissue (STt O) | Blood (STb tiers) | |
|---|---|---|
| Sample | Existing FFPE block or slides | A simple blood draw |
| Invasiveness | Uses tissue already taken | Non-invasive and repeatable |
| Tumour content | Often high | Depends on DNA shedding |
| Repeat testing | Needs a new sample | Easy to repeat over time |
| Best when | A good block exists | Surgery is difficult, or monitoring is planned |
05
Sample requirements and limits
An adequate, representative block with sufficient tumour content is required. Our team advises on suitability before you commit.
Tissue results reflect the sampled region of a tumour, which can be heterogeneous. That is one reason blood-based monitoring is a valuable complement.
Being clear about our limits
What we do and do not do
What we DO
- Profile a tumour block comprehensively, with immune and PGx
- Report mutational signatures and copy-number changes
- Feed a complete, tumour-board-signed report
- Advise on sample suitability before you commit
What we DON’T do
- Diagnose or decide treatment on its own
- Overcome tumour heterogeneity from one sampled region
- Proceed without an adequate sample
- Guarantee drug availability, approval, cover or benefit
Plain-language glossary (9 terms)
| Term | What it means |
|---|---|
| ctDNA | Circulating tumour DNA, tumour fragments in blood that a liquid biopsy reads. |
| SNV / InDel | A single-letter DNA change, or a small insertion or deletion. |
| Fusion | Two genes joined abnormally, creating a driver that is often highly treatable. |
| CNV | Copy-number variation, extra or missing copies of a gene. |
| TMB | Tumour mutational burden, how many mutations a tumour carries. |
| MSI / MMR | Signals of faulty DNA repair that often predict immunotherapy response. |
| PGx | Pharmacogenomics, how your genes affect the way you handle specific drugs. |
| Tumour fraction | How much of the blood DNA came from the tumour. |
| CCR | Complete coding region, meaning the whole gene is read rather than known hotspots. |
Important information and regulatory status
Signature STt O is a genomic (DNA-based) test for use by qualified healthcare professionals. It supports clinical judgement, it does not replace it, and it must be read alongside your full clinical history and applicable guidelines.
- A result is not a diagnosis and does not by itself decide treatment.
- A “not detected” result does not rule out cancer or a genetic change.
- Not all cancers release enough DNA into blood to be detected.
- We cannot guarantee that a medicine will be available, approved, covered or effective.
- Collection kits are for qualified phlebotomists. They are not for self-testing.
- Confirmatory testing may be required.
Regulatory status (India). Registration of our genomic tests as in-vitro diagnostic (IVD) medical devices with CDSCO is in progress, with the IVD class pending. Sequencing and variant calling are done by an accredited laboratory partner (CAP-accredited, ISO 15189) following ACMG/AMP/ASCO/CAP guidelines and a CE-IVD certified variant database. The OnKommon interpretation engine is provided for research and decision-support use. Marketing follows the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954.
Take the next step
Three ways forward. Pick the one that fits today.
Begin Blueprint Care
Commission your decision report and a dedicated clinical team.
Explore Blueprint CareAsk on WhatsApp, free
Signal replies to your first question within four hours, at no cost.
Start with Signal